



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION	ATTORNEY DOCKET NO.
09/331,127	8607-023-999

10/19/99 MUNROE

HM22/0807


PENNIE & EDMONDS
1165 AVENUE OF THE AMERICAS
NEW YORK NY 10036-2711

EXAMINER	
FITZGERALD, D	
ART UNIT	PAPER NUMBER

1647
DATE MAILED: 08/07/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: Commissioner of Patents and Trademarks
Washington, D.C. 20231

09/331,127

SERIAL NUMBER	DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
---------------	------	-----------------------	---------------------

EXAMINER

ART UNIT	PAPER NUMBER
----------	--------------

6

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, it fails to comply with the requirements of 37 CFR §§ 1.821-1.825 as set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR §§ 1.821-1.825.

Failure to comply with these rules will result in **abandonment** of the application under 37 CFR § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication should be directed to the undersigned at telephone number (703) 308-3934 or fax number (703) 308-0294. Inquiries of a general nature or relating to the status of the application should be directed to the Technology Center 1600 receptionists at (703) 308-0196.

DAVID L. FITZGERALD
PRIMARY EXAMINER
ART UNIT 1647

2 August 2000



Applicant Serial No. 09/331,127

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. §§ 1.821-1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990, and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. § 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. § 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. §§ 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing".
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. § 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. § 1.821(e).
- ☐ 7. Other:

Applicant must provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. § 1.821(e) or § 1.821(f) or § 1.821(g) or § 1.825(b) or § 1.825(d).

For questions regarding compliance with these requirements, please contact one of the following:

For rules interpretation, call (703) 308-4216.
For CRF submission help, call (703) 308-4212.
For PatentIn software help, call (703) 557-0400.

Please return a copy of this notice with your response.